Edwards(US:EW) ZACKSยท2025-04-18 14:20Core Viewpoint - Analysts expect Edwards Lifesciences to report quarterly earnings of $0.60 per share, reflecting a year-over-year decline of 9.1%, with revenues projected at $1.4 billion, down 12.2% from the previous year [1] Earnings Estimates - Changes in earnings estimates are crucial for predicting investor reactions to stock performance, with empirical studies showing a strong correlation between earnings estimate revisions and short-term price performance [2] Key Metrics Overview - Analysts predict 'Net Sales by Product Group- Transcatheter Mitral and Tricuspid Therapies' will reach $113.82 million, indicating a year-over-year increase of 56.1% [4] - 'Net Sales by Product Group- Surgical Structural Heart' is forecasted to be $254.51 million, reflecting a decrease of 4.4% from the year-ago quarter [4] - 'Net Sales by Product Group- Transcatheter Aortic Valve Replacement' is expected to reach $1.03 billion, showing a year-over-year increase of 2.2% [5] - 'Net Sales- Europe' is projected at $357.01 million, indicating a decline of 2.9% from the prior-year quarter [5] - 'Net Sales- Outside of the United States' is estimated at $573.77 million, reflecting a year-over-year decrease of 12.7% [6] - 'Net Sales- United States' is expected to be $849.03 million, down 9.8% from the previous year [6] - 'Net Sales- Japan' is projected to reach $96.40 million, indicating a year-over-year decline of 13% [6] - 'Net Sales- Rest of World' is expected to be $120.36 million, reflecting a significant decrease of 32.7% from the year-ago quarter [7] Stock Performance - Edwards Lifesciences shares have increased by 0.8% over the past month, contrasting with the Zacks S&P 500 composite's decline of 6.9%, with a Zacks Rank of 3 (Hold) indicating expected performance in line with the overall market [7]